8-K: Karyopharm Therapeutics Reports Q3 2024 Results, Narrows Revenue Guidance

Karyopharm Therapeutics announced its third quarter 2024 financial results, highlighted by $38.8 million in total revenue and a narrowed full-year revenue guidance.

Summary

• Karyopharm Therapeutics reported a total revenue of $38.8 million for the third quarter of 2024, compared to $36.0 million in the same period of 2023.
• U.S. XPOVIO net product revenue reached $29.5 million in Q3 2024, slightly down from $30.2 million in Q3 2023 but up from $28.0 million in Q2 2024.
• The company has narrowed its full-year 2024 total revenue guidance to $145.0 million to $155.0 million and U.S. XPOVIO net product revenue guidance to $110.0 million to $115.0 million.
• R&D and SG&A expenses are projected to be between $255.0 million and $265.0 million for the full year 2024.
• A change in the Phase 3 SENTRY trial co-primary endpoint to Abs-TSS from TSS50 was made following FDA alignment.
• The SENTRY trial sample size has been increased to approximately 350 patients to enhance statistical power, with top-line data expected in the second half of 2025.
• The company's cash, cash equivalents, and investments totaled $133.9 million as of September 30, 2024, and are expected to fund operations into the first quarter of 2026, excluding debt repayments and minimum liquidity covenants.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the continued revenue growth and clinical trial progress, but there are concerns about the slight decrease in XPOVIO revenue compared to the previous year, the net loss, and the company's cash position. The change in the SENTRY trial endpoint is a positive development, but the company's financial situation requires careful monitoring.

Positives

• Karyopharm achieved its third consecutive quarter of U.S. XPOVIO net product revenue growth.
• There was continued quarter-over-quarter demand growth for XPOVIO, particularly in the community setting.
• Global patient access for selinexor expanded with favorable reimbursement decisions in France and Italy and additional regulatory approvals in several countries.
• The change to Abs-TSS as a co-primary endpoint in the SENTRY trial is seen as a positive development, reflecting a growing willingness by the FDA to incorporate more sensitive methods of evaluating symptoms.
• The company is proactively increasing the sample size of the SENTRY trial to further increase statistical powering.
• License and other revenue increased to $9.3 million in Q3 2024, compared to $5.8 million in Q3 2023, primarily due to milestone-related revenue from Menarini.
• SG&A expenses decreased to $27.6 million in Q3 2024, compared to $30.8 million in Q3 2023, due to cost reduction initiatives.

Negatives

• U.S. XPOVIO net product revenue decreased slightly to $29.5 million in Q3 2024, compared to $30.2 million in Q3 2023.
• Interest expense increased to $11.4 million in Q3 2024, compared to $6.1 million in Q3 2023, due to new term loans and secured convertible senior notes.
• The company reported a net loss of $32.1 million for Q3 2024.
• Cash, cash equivalents, and investments decreased to $133.9 million as of September 30, 2024, compared to $192.4 million as of December 31, 2023.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt.
• There are risks associated with the commercialization of XPOVIO and the clinical development of other drug candidates.
• The company faces competition in the multiple myeloma marketplace.
• The company's financial performance is subject to various factors, including the adoption of XPOVIO, regulatory approvals, and clinical trial results.
• The company's cash runway is dependent on revenue generation, license agreements, and expense management.
• The company needs to repay $24.5 million in convertible notes due in October 2025 and maintain a $25.0 million minimum liquidity covenant.

Future Outlook

Karyopharm has narrowed its full-year 2024 revenue guidance and expects its current cash position to fund operations into the first quarter of 2026, excluding debt repayments and minimum liquidity covenants. The company anticipates top-line data readouts from key clinical trials in the coming years.

Management Comments

• Richard Paulson, President and CEO, stated that the company delivered its third consecutive quarter of U.S. XPOVIO net product revenue growth.
• Richard Paulson also expressed excitement about the change to the Phase 3 SENTRY myelofibrosis trial endpoints following engagement with the FDA.
• Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY trial, noted the significant unmet need in myelofibrosis and the encouraging results from the Phase 1 trial of selinexor and ruxolitinib combination.

Industry Context

This announcement comes as Karyopharm continues to navigate the competitive landscape of cancer therapies, particularly in multiple myeloma. The company's focus on novel mechanisms of action, such as XPO1 inhibition, positions it as a potential disruptor in the field. The change in the SENTRY trial endpoint reflects a broader trend towards more sensitive measures of patient outcomes in clinical trials.

Comparison to Industry Standards

• The reported Q3 2024 revenue of $38.8 million is a modest increase compared to the $36.0 million in Q3 2023, indicating steady but not explosive growth. This is in line with other commercial-stage biotech companies focused on niche oncology markets.
• The U.S. XPOVIO net product revenue of $29.5 million is a slight decrease from $30.2 million in Q3 2023, which could be a concern given the competitive landscape. Companies like Bristol Myers Squibb (BMS) with their multiple myeloma drugs (e.g., Revlimid, Pomalyst) and Johnson & Johnson (JNJ) with Darzalex are major competitors.
• The change in the SENTRY trial endpoint to Abs-TSS is a significant move. Other companies like Incyte (with Jakafi) and CTI BioPharma (with Vonjo) have used SVR35 as a primary endpoint in myelofibrosis trials. The shift to Abs-TSS suggests a focus on patient-reported outcomes, which is becoming increasingly important in regulatory approvals.
• The company's cash position of $133.9 million is relatively low for a company with multiple ongoing Phase 3 trials. Companies like Exelixis (EXEL) and BeiGene (BGNE) typically maintain larger cash reserves to fund their extensive clinical programs. Karyopharm's cash runway into Q1 2026 (excluding debt) is a concern, especially given the need to repay convertible notes in 2025.
• The R&D and SG&A expense guidance of $255.0 million to $265.0 million is substantial, reflecting the high cost of clinical development. This is comparable to other biotech companies with similar pipelines, but the company needs to demonstrate a clear path to profitability to justify these expenses.

Stakeholder Impact

• Shareholders will be interested in the company's revenue growth, clinical trial progress, and cash runway.
• Employees will be impacted by the company's cost reduction initiatives and headcount changes.
• Patients will benefit from the development of new cancer therapies.
• Creditors will be concerned about the company's debt obligations and cash position.
• Suppliers will be impacted by the company's financial performance and ability to pay its bills.

Next Steps

• The company will continue to enroll patients in the SENTRY and XPORT-EC-042 trials.
• The company expects to present preliminary data from the SENTRY-2 trial in late 2024 or early 2025.
• The company will provide guidance on the top-line data readout timeline for the XPORT-MM-031 trial pending regulatory agency feedback.
• The company will continue to monitor and manage its expenses.
• The company will host a conference call to discuss the Q3 2024 results.

Key Dates

Keywords

Karyopharm, XPOVIO, selinexor, myelofibrosis, endometrial cancer, multiple myeloma, clinical trial, revenue, FDA, SENTRY trial, pharmaceutical, oncology